RT Journal Article
SR Electronic
T1 Ibuprofen efficacy, tolerability and safety in obese children: a systematic review
JF Archives of Disease in Childhood
JO Arch Dis Child
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP archdischild-2022-324652
DO 10.1136/archdischild-2022-324652
A1 Eman Shamsaee
A1 Alaw Huws
A1 Andrea Gill
A1 Stephen J McWilliam
A1 Daniel B Hawcutt
YR 2022
UL http://adc.bmj.com/content/early/2022/11/15/archdischild-2022-324652.abstract
AB Objective Childhood obesity can affect drug disposition and efficacy of ibuprofen. The primary objective was to assess efficacy of ibuprofen in obese children.Design A systematic review was undertaken following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology. Studies were identified from 12 databases. Two independent reviewers evaluated studies against the inclusion criteria and assessed for methodological quality.Setting Any clinical setting.Patients Patients under 18 years who were overweight/obese.Interventions Patients taking ibuprofen for any indication, dose or regimen.Main outcome measures The efficacy and tolerability of ibuprofen treatment in obese children and presence of any adverse drug reactions.Results Searches identified 1305 studies. Four studies met inclusion criteria: three retrospective cohort studies (n=583, median age: 6 years, range: 1–18 years; n=200, median age: 11 years, range: 3–18 years; n=358 median age: 3.1 years, range: 1.2–8.5 years, respectively) and one case study. Each study differed in their method of dosing ibuprofen (weight-based, age-based and adjusted body weight dosing). Various doses were used: 5 mg/kg every 6 hours, 400 mg three times a day, 120 mg/dose and a dose calculated using adjusted body weight. One study reported efficacy (obese n=189, non-obese, n=394), where adequate pain control was achieved using 5 mg/kg. The other three studies did not determine if efficacy differed between obese and non-obese children.One study described adverse effects. An increased risk of bleeding with ibuprofen was noted but did not differentiate between obese and non-obese children.Conclusion There are little published data to guide clinicians prescribing ibuprofen in obese children.PROSPERO registration number CRD42021213500.Data are available on request from the authors.